DE69909775D1 - Neue fettanaloge zur behandlung von diabetes - Google Patents

Neue fettanaloge zur behandlung von diabetes

Info

Publication number
DE69909775D1
DE69909775D1 DE69909775T DE69909775T DE69909775D1 DE 69909775 D1 DE69909775 D1 DE 69909775D1 DE 69909775 T DE69909775 T DE 69909775T DE 69909775 T DE69909775 T DE 69909775T DE 69909775 D1 DE69909775 D1 DE 69909775D1
Authority
DE
Germany
Prior art keywords
sub
treating diabetes
new fat
analogs
fat analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69909775T
Other languages
English (en)
Other versions
DE69909775T2 (de
Inventor
Rolf Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thia Medica AS
Original Assignee
Thia Medica AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica AS filed Critical Thia Medica AS
Publication of DE69909775D1 publication Critical patent/DE69909775D1/de
Application granted granted Critical
Publication of DE69909775T2 publication Critical patent/DE69909775T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69909775T 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes Expired - Lifetime DE69909775T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/NO98/00143 1998-05-08
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000136 WO1999058122A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of diabetes

Publications (2)

Publication Number Publication Date
DE69909775D1 true DE69909775D1 (de) 2003-08-28
DE69909775T2 DE69909775T2 (de) 2004-06-03

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (18)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1285652B1 (de)
JP (3) JP2002514595A (de)
KR (3) KR100701502B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE336239T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331395C (de)
DE (5) DE69909775T2 (de)
DK (3) DK1075259T3 (de)
ES (3) ES2207253T3 (de)
HK (3) HK1034909A1 (de)
NO (3) NO20005461L (de)
NZ (3) NZ508047A (de)
PT (2) PT1075258E (de)
RU (3) RU2221558C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
CN100351259C (zh) * 2002-06-20 2007-11-28 Icvec有限公司 含硫的磷脂衍生物
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
EP1558237A4 (de) * 2002-09-27 2007-01-17 Martek Biosciences Corp VERBESSERTE BLUTZUCKERKONTROLLE F RPRû-DIABETES UND/ODER DIABETES TYP II UNTER VERWENDUNG VON DOCOSAHEXAENSûURE
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
WO2004071458A2 (en) * 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
EP1718602A4 (de) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Therapeutische und trägermoleküle
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20070259435A1 (en) * 2004-05-28 2007-11-08 Janssen Pharmaceutica N.V. Intravenous Drug Administration and Blood Sampling Model in the Awake Rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
KR20070054637A (ko) * 2004-07-19 2007-05-29 티아 메디카 에이에스 식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
CA2607247C (en) * 2005-05-04 2015-10-06 Pronova Biopharma Norge As .alpha.-substituted dha derivatives
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
PT2724722T (pt) * 2006-10-20 2017-03-14 Neurendo Pharma Llc Método de restaurar o efeito incretina
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
WO2008132552A2 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
EP2117301A4 (de) * 2007-02-26 2010-04-14 Yeda Res & Dev Verwendung langkettiger alkoholderivate zur behandlung von kreisrundem haarausfall
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
WO2009056983A1 (en) * 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009132979A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
TR201905768T4 (tr) 2009-05-08 2019-05-21 Basf As Kardiyovasküler, metabolik ve enflamatuar hastalık alanları ile ilişkili hastalıkların tedavisinde çoklu doymamış yağlı asitleri.
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP3284494A1 (de) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Tragbares infusionspumpensystem
WO2012016048A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti- viral azide-containing compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105120842B (zh) 2013-02-28 2020-12-01 普罗诺瓦生物医药挪威公司 包含脂质化合物、甘油三酯和表面活性剂的组合物以及使用它们的方法
EP2968568A2 (de) 2013-03-11 2016-01-20 Life Science Nutrition AS Natürliche lipide mit nicht oxidierbaren fettsäuren
US10154979B2 (en) 2013-03-11 2018-12-18 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
CN107405343A (zh) 2014-11-07 2017-11-28 明尼苏达大学董事会 可用于治疗疾病的盐和组合物
BR112017023164A2 (pt) 2015-04-28 2018-07-24 Pronova Biopharma Norge As composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
KR20200075815A (ko) * 2017-10-23 2020-06-26 에피트래커, 인코포레이티드 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도
IL308604A (en) 2017-12-06 2024-01-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
WO2020180814A1 (en) * 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DK0843972T3 (da) * 1996-11-20 2002-12-02 Nutricia Nv Næringsmiddelsammensætning, der indeholder fedtstoffer til behandling af stofskiftesygdomme
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
CN1300211A (zh) 2001-06-20
CA2331408C (en) 2008-10-21
DK1075260T3 (da) 2006-02-06
DE69910559T2 (de) 2004-06-17
US6417232B1 (en) 2002-07-09
NO20005463L (no) 2001-01-08
WO1999058123A2 (en) 1999-11-18
NO20005461L (no) 2001-01-08
DE69910559D1 (de) 2003-09-25
KR20010043315A (ko) 2001-05-25
ATE245416T1 (de) 2003-08-15
PT1075258E (pt) 2004-01-30
ATE306916T1 (de) 2005-11-15
DE69927805D1 (de) 2006-03-02
AU761355B2 (en) 2003-06-05
CN1300212A (zh) 2001-06-20
ATE247464T1 (de) 2003-09-15
ES2204142T3 (es) 2004-04-16
DE69932864D1 (de) 2006-09-28
NO20005462D0 (no) 2000-10-30
DE69932645D1 (de) 2006-09-14
RU2219920C2 (ru) 2003-12-27
RU2223095C2 (ru) 2004-02-10
HK1034909A1 (en) 2001-11-09
CN1244323C (zh) 2006-03-08
KR20010043316A (ko) 2001-05-25
KR100822077B1 (ko) 2008-04-14
ES2251218T3 (es) 2006-04-16
AU762792B2 (en) 2003-07-03
KR100701503B1 (ko) 2007-04-02
HK1034911A1 (en) 2001-11-09
DE69927805T2 (de) 2006-07-06
JP2002514595A (ja) 2002-05-21
CA2331395C (en) 2008-10-14
JP2002514594A (ja) 2002-05-21
DK1075259T3 (da) 2003-11-03
AU4936699A (en) 1999-11-29
JP4465672B2 (ja) 2010-05-19
ATE334666T1 (de) 2006-08-15
CA2331393C (en) 2009-08-11
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
US6441036B1 (en) 2002-08-27
KR100701502B1 (ko) 2007-04-02
WO1999058122A1 (en) 1999-11-18
NZ508046A (en) 2003-08-29
NO20005461D0 (no) 2000-10-30
AU4936799A (en) 1999-11-29
BR9910296A (pt) 2002-01-15
WO1999058121A1 (en) 1999-11-18
CA2331408A1 (en) 1999-11-18
JP5057003B2 (ja) 2012-10-24
US20020198259A1 (en) 2002-12-26
NZ508045A (en) 2003-08-29
EP1285652B1 (de) 2006-08-16
EP1284139A1 (de) 2003-02-19
WO1999058123A3 (en) 2000-03-09
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
EP1285652A1 (de) 2003-02-26
US6365628B1 (en) 2002-04-02
AU5451799A (en) 1999-11-29
RU2221558C2 (ru) 2004-01-20
AU7240398A (en) 1999-11-29
CA2331393A1 (en) 1999-11-18
NZ508047A (en) 2003-05-30
EP1075259A1 (de) 2001-02-14
CN1245157C (zh) 2006-03-15
EP1075260A2 (de) 2001-02-14
ATE336239T1 (de) 2006-09-15
NO333143B1 (no) 2013-03-18
CN1302204A (zh) 2001-07-04
CA2331395A1 (en) 1999-11-18
DK1075258T3 (da) 2003-12-01
DE69909775T2 (de) 2004-06-03
NO20005463D0 (no) 2000-10-30
EP1284139B1 (de) 2006-08-02
EP1075259B1 (de) 2003-07-23
CN1223343C (zh) 2005-10-19
WO1999058120A1 (en) 1999-11-18
AU762790B2 (en) 2003-07-03
NO20005462L (no) 2001-01-08
EP1075258B1 (de) 2003-08-20
US7026356B2 (en) 2006-04-11
EP1075258A1 (de) 2001-02-14
PT1075259E (pt) 2003-12-31
JP2002514596A (ja) 2002-05-21
KR20010043314A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
DE69909775D1 (de) Neue fettanaloge zur behandlung von diabetes
ES2158273T3 (es) Proceso y composicion de blanqueo.
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DK0554343T3 (da) Liposomer af kurvand stabiliseret i en DNA-gel
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
FR2396015A1 (fr) Derives de l'acetylene, leur procede de preparation et leur utilisation comme inhibiteurs de monoamine-oxydases pour traiter notamment un etat depressif ou de l'hypertension
DE69623767T2 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
DE60204014D1 (de) Chlormethylierung von thiophene
DE69109293T2 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
ATE163344T1 (de) Zusammensetzungen zur behandlung von geernteter pflanzenmaterial

Legal Events

Date Code Title Description
8364 No opposition during term of opposition